| __timestamp | Blueprint Medicines Corporation | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 72429000 |
| Thursday, January 1, 2015 | 14456000 | 78634000 |
| Friday, January 1, 2016 | 19218000 | 75374000 |
| Sunday, January 1, 2017 | 27986000 | 92157000 |
| Monday, January 1, 2018 | 47928000 | 93326000 |
| Tuesday, January 1, 2019 | 96388000 | 103132000 |
| Wednesday, January 1, 2020 | 157743000 | 110171000 |
| Friday, January 1, 2021 | 195293000 | 218817000 |
| Saturday, January 1, 2022 | 237374000 | 233827000 |
| Sunday, January 1, 2023 | 295141000 | 267194000 |
| Monday, January 1, 2024 | 359272000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical and healthcare sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for operational efficiency. Over the past decade, Blueprint Medicines Corporation and Lantheus Holdings, Inc. have demonstrated contrasting trajectories in their SG&A expenditures.
From 2014 to 2023, Blueprint Medicines saw a staggering increase in SG&A expenses, growing nearly 3,600% from $7.89 million to approximately $295 million. This reflects the company's aggressive expansion and investment in administrative capabilities.
Conversely, Lantheus Holdings experienced a more moderate growth of around 270% in the same period, from $72 million to $267 million. This suggests a more controlled approach to scaling operations.
These trends highlight the strategic differences in managing operational costs, offering valuable insights for investors and industry analysts.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Lantheus Holdings, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.